How to Get Lantus in Michigan: Prescriptions, Telehealth, and Pharmacy Access

Published Jan 15, 2025Last reviewed Jul 10, 2025

Image: HealthRX.com clinical image

Insulin glargine is a long-acting basal insulin analogue. Sanofi markets the original 100 units/mL version as Lantus; the same molecule is also sold as Basaglar (an authorized generic, 100 units/mL) and, at a higher concentration, as Toujeo (300 units/mL). These products are not automatically interchangeable, and a Michigan prescriber needs to specify concentration and brand on the prescription.

The direct answer: Michigan residents can obtain a Lantus prescription from any fully licensed Michigan physician, nurse practitioner, or physician assistant, either in person or through a telehealth visit that establishes a genuine patient-provider relationship (Michigan law does not allow a prescription based on an online questionnaire alone). Most Michigan Medicaid plans and commercial insurers cover Lantus but require prior authorization, and coverage rules change often enough that they need to be confirmed at the time of the visit rather than assumed from this article. The single biggest driver of how fast a Michigan patient actually gets medication in hand is not the prescribing step, which can often happen the same day, but whether insurance prior authorization is required before the pharmacy will dispense at a covered price.

This article separates what is stable (federal approval status, general Michigan prescribing law, clinical dosing guidance) from what changes often (specific insurer PA rules, Medicaid formulary status, cash prices) and gives a checklist for verifying the latter before a patient relies on it.

Why basal insulin comes up so often in Michigan diabetes care

The CDC's state diabetes data indicate that diabetes affects a substantial share of Michigan adults, and many people with type 1 diabetes and a meaningful subset of people with type 2 diabetes eventually need basal insulin when oral agents and GLP-1 receptor agonists are not enough to reach glycemic targets (CDC diabetes data). Insulin glargine's defining pharmacologic feature is a relatively flat, long-duration action profile that avoids the pronounced peak seen with NPH insulin, which is why it is commonly chosen as a once-daily basal option. The FDA approved insulin glargine (marketed as Lantus) in 2000; current labeling can be located through the FDA's Drugs@FDA database (accessdata.fda.gov).

A large, widely cited cardiovascular outcomes trial (published in the New England Journal of Medicine in 2012, commonly referred to as the ORIGIN trial) followed more than 12,000 participants with dysglycemia over several years and reported that basal insulin glargine, titrated toward a near-normal fasting glucose target, did not increase cardiovascular events compared with standard care. That is the general, well-established conclusion. Editors and clinicians should verify the exact hazard ratio and confidence interval against the primary publication before quoting a specific number, since the inherited citation for this trial in earlier drafts could not be verified against the correct paper and has been removed from this version pending confirmation.

Who can prescribe Lantus in Michigan

Physicians (MD/DO), nurse practitioners, and physician assistants who hold full Michigan licensure, or an equivalent multistate authority recognized in Michigan, can prescribe insulin glargine because it is a non-controlled prescription medication. In general terms:

Michigan-licensed physicians have independent prescribing authority for non-controlled medications.
Michigan nurse practitioners who meet the state's independent practice requirements can prescribe without a physician collaboration agreement; NPs who do not yet meet those requirements may need one.
Physician assistants in Michigan practice under a supervising or collaborating physician relationship, but that relationship does not itself narrow which non-controlled drugs a PA may prescribe within their scope of practice.

This summary describes the general shape of Michigan's prescribing framework. It does not cite a specific statute number, because the exact Michigan Compiled Laws sections were not independently verified for this draft and a wrong citation is worse than none. A patient or clinician who needs the precise statutory language should confirm it directly with the Michigan Department of Licensing and Regulatory Affairs (LARA) or Michigan legislature website rather than relying on a secondhand citation.

Telehealth prescribing across state lines is possible for physicians practicing under an Interstate Medical Licensure Compact privilege for Michigan, or for nurse practitioners licensed in Michigan or holding a compatible multistate license, provided a valid clinical relationship is established first.

Is a telehealth-only visit enough to start Lantus?

Michigan permits telehealth prescribing of non-controlled medications, including insulin glargine, when a synchronous audio-visual visit (or an in-person exam) establishes a genuine patient-provider relationship first. A prescription cannot legally rest on a questionnaire alone.

The American Diabetes Association's Standards of Care recommend that basal insulin initiation be paired with structured patient education covering injection technique, hypoglycemia recognition, and self-monitoring of blood glucose (ADA Standards of Care in Diabetes 2024). A telehealth visit that follows this guidance will generally ask for a recent A1c, glucose logs, and a current medication list before the prescriber issues the order. A patient who has never used insulin before should expect a longer visit than someone who is simply transferring an existing, stable regimen.

What is established: Michigan law allows telehealth prescribing of insulin glargine after a valid clinical relationship is formed, and clinical guidelines recommend education at initiation. What is plausible but not something this article can quantify: typical turnaround times from visit to prescription vary by platform and are not something a general reference page can state as a fixed number. What is not established: that any specific telehealth platform can guarantee a same-day fill; pharmacy stock, insurance PA, and shipping logistics all affect that independently of the prescribing step.

Labs a Michigan prescriber will likely want before starting Lantus

Four values commonly guide initial dosing and safety monitoring for basal insulin, consistent with general ADA guidance on diabetes management:

Hemoglobin A1c, anchors the glycemic target and how aggressively the dose should be titrated.
Fasting plasma glucose, the typical anchor value used for basal insulin titration algorithms.
Basic metabolic panel, renal function affects hypoglycemia risk and which adjunct medications are appropriate.
TSH, particularly for people with type 1 diabetes, autoimmune thyroid disease occurs more often in people with type 1 diabetes than in the general population. The exact co-prevalence figure varies across studies and should be verified against a specific primary source rather than quoted as a fixed percentage.

Most telehealth platforms will accept lab results from any accredited Michigan laboratory. If a patient has no recent labs, ordering them first will add time to the process; this article cannot state a universal number of added days because it depends on the lab and the platform.

Does Michigan Medicaid cover Lantus, and what does prior authorization involve?

Michigan Medicaid has historically covered insulin glargine for type 1 and type 2 diabetes with prior authorization, and insulin glargine has generally been treated as a preferred product on the Medicaid formulary when PA criteria are met. Because Medicaid preferred drug lists and PA criteria are reviewed and updated on a recurring basis, a patient or prescriber should confirm the current Michigan Medicaid Provider Manual and preferred drug list directly rather than relying on a stated status here (as of the last review date above).

Typical prior authorization criteria for basal insulin, in general terms seen across Medicaid and commercial plans, include a confirmed diabetes diagnosis, documentation of the prescriber's management of the patient, a clinical rationale for a long-acting analogue over an older option such as NPH, and recent glucose data. Standard PA review and expedited review for urgent clinical situations are both commonly available, but exact turnaround windows differ by payer and are not stated here as fixed numbers because they change and were not independently verified for this draft.

Private insurers operating in Michigan generally use similar PA logic. Some professional organizations have raised concerns that PA delays for insulin can worsen glycemic control, though a specific study should be checked directly before citing a numeric association, since the source citation for that claim could not be verified for this draft.

Manufacturer patient assistance programs exist for Lantus, and separate state-level assistance programs may also apply. Because program eligibility, caps, and enrollment steps change, a patient should confirm current terms directly with the manufacturer's savings program page or the Michigan Department of Health and Human Services rather than relying on a specific dollar figure quoted in a general article.

Transferring an existing Lantus prescription into Michigan

Insulin glargine is not a federally controlled substance, so the interstate transfer restrictions that apply to controlled medications do not apply here. In general, a patient moving to Michigan with refills remaining on an out-of-state prescription can ask a Michigan-licensed pharmacy to contact the original pharmacy and transfer the remaining refills, providing the prescriber's name, NPI number, and the patient's date of birth. Michigan has a large number of licensed retail pharmacies across major chains and independents; an exact statewide count is not something this article states as fixed, since licensing rosters change.

If the original prescription was paper-only and no refills remain, the receiving pharmacy may need the original prescriber to send a new electronic order, or the patient may need a new Michigan telehealth visit to establish a new prescription.

Compounded insulin glargine: what 503A pharmacies can and cannot do

Some Michigan-licensed 503A compounding pharmacies compound patient-specific insulin glargine preparations under a valid prescription and a documented medical need, operating under Michigan's Pharmacy Practice Act and federal FDCA Section 503A rules. The FDA's compounding guidance states plainly that compounded drug products, including compounded insulin, are not FDA-approved and should not be used as a substitute for a commercially available, appropriate product when one exists (FDA compounding laws and policies). A prescriber needs to document the specific medical reason for a compounded formulation rather than choosing it by default.

Documented reasons patients sometimes need a compounded formulation include a confirmed hypersensitivity to an excipient in the commercial product, or a need for a non-standard concentration that is not commercially manufactured. This is a clinical decision made with a prescriber, not a general recommendation, and this article does not provide individualized guidance on when compounding is appropriate for a specific patient.

A Michigan 503A pharmacy generally ships compounded insulin only to Michigan residents unless it holds separate nonresident pharmacy licenses in other states. Confirm current Michigan Board of Pharmacy licensure directly before accepting a compounded shipment.

A practical path through the process

Gather documentation. Recent A1c (ideally within the past year), current medication list, insurance information, and any CGM data.
Choose a prescriber. An in-person primary care or endocrinology visit works well for comprehensive management. A telehealth visit is often faster for an established insulin user who mainly needs a new Michigan-valid prescription. Urgent or hospital-based care is appropriate for acute hyperglycemia or suspected diabetic ketoacidosis and should not wait for a routine appointment.
Complete the visit and receive the electronic prescription, sent to the pharmacy of the patient's choice.
Address prior authorization if the insurer requires it. This step, not the clinical visit, is usually the rate-limiting factor for how long the whole process takes.
Fill the prescription. Retail pharmacies commonly stock Lantus vials and SoloStar pens; mail-order adds shipping time beyond in-store pickup.

Total time from first contact to medication in hand can be as short as same day for a cash-pay patient near a stocked pharmacy, or considerably longer if prior authorization, lab collection, or pharmacy backorder are involved. This article does not state a single universal number for that timeline because it depends on insurance status and pharmacy inventory, both of which are outside a prescriber's control.

Dosing basics a Michigan prescriber will discuss

General ADA and AACE-aligned practice starts basal insulin at a conservative dose, commonly around 10 units once daily or a weight-based starting dose for larger patients, with structured up-titration based on fasting glucose readings over several days. For type 1 diabetes, basal insulin typically makes up a substantial minority to about half of total daily insulin dose, with the rest delivered as prandial rapid-acting insulin. Injection site rotation within one anatomical area (commonly the abdomen) and correct storage of opened vials or pens at room temperature for a limited number of weeks are standard patient education points. This article does not provide an individualized dose; dose titration must be set by the prescriber managing the specific patient.

Common access barriers in Michigan

Cost without insurance. Manufacturer savings programs and pharmacy discount cards can meaningfully lower cash price for eligible patients, but list prices and discount amounts change over time and by pharmacy. Confirm current pricing directly with the pharmacy and the manufacturer's savings program rather than relying on a number in a general article.

Rural access. Endocrinology specialists are concentrated in Michigan's larger metro areas. Telehealth reduces, but does not eliminate, the travel burden for patients in the Upper Peninsula and northern Lower Michigan; a specific percentage of endocrinologists located outside major metros is not stated here because it was not independently verified for this draft.

Language access. Michigan Medicaid requires interpreter access for patients with limited English proficiency, and several telehealth platforms serving Michigan's Detroit-area population offer interpretation in languages including Spanish, Arabic, and Somali.

Prescriber turnover. A patient whose previous Michigan prescriber has retired or left practice can usually re-establish care through a telehealth visit and get a bridge prescription without an extended gap in supply.

Verification checklist: stable facts vs. facts that change

Use this to separate what a patient can treat as settled from what must be re-checked before acting on it.

Stable, unlikely to change soon (federal and clinical framework):

Insulin glargine is FDA-approved and prescription-only; it is not a controlled substance.
Michigan law permits telehealth prescribing of non-controlled medications once a valid patient-provider relationship is established through a synchronous visit or in-person exam.
503A compounded insulin is not FDA-approved and is intended only for documented, patient-specific medical need, not as a routine substitute.
ADA-aligned clinical practice recommends structured education (injection technique, hypoglycemia recognition, glucose monitoring) at basal insulin initiation.
Basaglar, Lantus, and Toujeo are all insulin glargine but differ in concentration or manufacturer status and are not automatically interchangeable.

Date-sensitive, must be re-verified before a patient relies on it (confirm at the time of the visit or fill):

Whether a specific insurer or Michigan Medicaid plan currently requires prior authorization for Lantus, and the exact PA criteria in effect.
Current Michigan Medicaid preferred drug list status for insulin glargine products.
Standard and expedited PA turnaround times for a specific payer.
Current cash price at a specific Michigan pharmacy, and current terms of any manufacturer or discount program.
Whether a specific telehealth platform or prescriber can see a new patient same day, and which Michigan pharmacies currently have a given formulation in stock.
Whether a specific 503A pharmacy currently holds active Michigan Board of Pharmacy licensure.

If a fact falls in the second column, treat anything printed in a general reference article, including this one, as a starting point to confirm, not a final answer.

When to seek urgent care instead of scheduling a routine visit

Symptoms of very high blood glucose with nausea, vomiting, abdominal pain, rapid breathing, or confusion can indicate diabetic ketoacidosis or a severe hyperglycemic state and warrant emergency evaluation rather than a routine telehealth appointment or a wait for prior authorization to clear. Similarly, symptoms of severe hypoglycemia (confusion, loss of consciousness, inability to safely treat with oral carbohydrate) require emergency care.

Frequently asked questions

Can a physician assistant prescribe Lantus in Michigan? Yes, within their scope of practice and their required collaborating physician relationship. The collaboration requirement governs the practice relationship generally; it does not single out insulin glargine for extra restriction.

Is insulin glargine the same drug as Basaglar or Toujeo? All three contain insulin glargine, but Basaglar is an authorized generic at the same 100 units/mL concentration as Lantus, and Toujeo is a higher, 300 units/mL concentration used for patients who need a large basal dose in a smaller injection volume. A prescriber needs to specify which product and concentration when writing the Michigan prescription; they are not automatically interchangeable.

Does a compounded version of Lantus work the same as the commercial product? It is not FDA-approved, and the FDA specifically advises against using compounded versions of a drug as a substitute when the commercially manufactured product is available and appropriate for the patient. Compounding is reserved for documented individual medical need, decided with a prescriber.

Will insurance prior authorization delay my first dose? It can. Prior authorization, where required, is generally the slowest step in the process, more so than the clinical visit itself. Ask the prescribing platform or clinic whether they submit PA requests on the patient's behalf and how they typically handle expedited requests for urgent clinical situations.

References

Centers for Disease Control and Prevention. Diabetes Data and Statistics. https://www.cdc.gov/diabetes/data/index.html
U.S. Food and Drug Administration. Drugs@FDA database (Lantus prescribing information). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1). https://diabetesjournals.org/care/article/47/Supplement_1/S1/153946/Introduction-Standards-of-Care-in-Diabetes-2024
U.S. Food and Drug Administration. Human Drug Compounding: Laws and Policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
U.S. Food and Drug Administration, general reference. https://www.fda.gov/

Note for editorial review: the previous draft's citations for the ORIGIN trial (PMID 22686416), the thyroid co-prevalence meta-analysis (PMID 30889785), and the AACE prior-authorization consensus statement (PMID 37180409) could not be verified against the correct primary source for this rewrite and have been removed from in-text citation pending confirmation by a qualified reviewer with direct database access. Specific Michigan statute citations (MCL numbers), Medicaid PA turnaround times, cash prices, and pharmacy counts have been generalized or flagged for the same reason. A quoted passage attributed to the ADA Standards of Care in the prior draft could not be confirmed as an exact quotation and has been converted to paraphrase.